These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 32422564)

  • 21. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
    Pham MM; Hinchcliff E; Avila M; Westin SN
    Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
    Ruscito I; Bellati F; Ray-Coquard I; Mirza MR; du Bois A; Gasparri ML; Costanzi F; De Marco MP; Nuti M; Caserta D; Pignata S; Dorigo O; Sehouli J; Braicu EI
    Cancer Treat Rev; 2020 Jul; 87():102040. PubMed ID: 32485510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
    Washington C; Gunderson CC; Moore KN
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):4-11. PubMed ID: 30451713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
    Xu J; Dai Y; Gao Y; Chai R; Lu C; Yu B; Kang Y; Xu C
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.
    Tao M; Sun F; Wang J; Wang Y; Zhu H; Chen M; Liu L; Liu L; Lin H; Wu X
    Pharmacol Res; 2022 May; 179():106232. PubMed ID: 35462012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
    Kurnit KC; Avila M; Hinchcliff EM; Coleman RL; Westin SN
    Pharmacol Ther; 2020 Sep; 213():107588. PubMed ID: 32450190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in
    Färkkilä A; Rodríguez A; Oikkonen J; Gulhan DC; Nguyen H; Domínguez J; Ramos S; Mills CE; Pérez-Villatoro F; Lazaro JB; Zhou J; Clairmont CS; Moreau LA; Park PJ; Sorger PK; Hautaniemi S; Frias S; D'Andrea AD
    Cancer Res; 2021 May; 81(10):2774-2787. PubMed ID: 33514515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.
    Romeo M; Pardo JC; Martínez-Cardús A; Martínez-Balibrea E; Quiroga V; Martínez-Román S; Solé F; Margelí M; Mesía R
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
    Jiang X; Li X; Li W; Bai H; Zhang Z
    J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of PARP Inhibitor Resistance.
    O'Connor MJ; Forment JV
    Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer.
    McMellen A; Yamamoto TM; Qamar L; Sanders BE; Nguyen LL; Ortiz Chavez D; Bapat J; Berning A; Post MD; Johnson J; Behbakht K; Nurmemmedov E; Chuong EB; Bitler BG
    Mol Cancer Res; 2023 Jan; 21(1):3-13. PubMed ID: 36149636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis.
    Wang M; Yuan C; Wu Z; Xu M; Chen Z; Yao J; Que Z; Tian J; Leung EL; Wang Z
    Int J Biol Sci; 2024; 20(7):2454-2475. PubMed ID: 38725854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
    Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
    Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.